Saturday, June 25 2022

NEW YORK–(BUSINESS WIRE)–The law firm Kirby McInerney LLP investigation of potential claims against GoodRx Holdings, Inc. (“GoodRx” or the “Company”) (NASDAQ: GDRX). The investigation focuses on whether GoodRx violated federal securities laws and/or engaged in other illegal business practices.

GoodRx’s core business is a healthcare technology platform that provides consumers with a prescription discount card to get discounted prices on prescription drugs.

On February 28, 2022, after market close, GoodRx reported disappointing fourth quarter 2021 and full year results and offered poor guidance for 2022. At this news, GoodRx stock price fell $10.66 per share, or approximately 38.9%, from $27.40 per share to close at $16.74 per share on March 1, 2022.

On May 9, 2022, GoodRx announced its first quarter 2022 financial results and withdrew its fiscal 2022 guidance. impacted discount acceptance of most PBMs for a subset of drugs.” The Company expects that “the question of the grocer . . . could impact revenue estimated at around $30 million [and] will continue without improvement until the second quarter. “As a result, GoodRx” believes[s] it’s quite unlikely [it] will be able to meet the guidance for fiscal year 2022” previously provided. On this news, GoodRx stock price declined $2.78 per share, or approximately 25.86%, from $10.75 per share to close at $7.97 on May 10, 2022.

If you have purchased or otherwise acquired GoodRx securities, have information or would like to know more about this survey, please contact Thomas W. Elrod of Kirby McInerney LLP by email to [email protected], or by completing this Contact formto discuss your rights or interests in relation to these matters at no cost to you.

Kirby McInerney LLP is a New York-based law firm specializing in securities, antitrust, whistleblower and consumer litigation. The company’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm is available on the Kirby McInerney LLP website:

This press release may be considered attorney advertising in certain jurisdictions under applicable law and ethics rules.


INVESTIGATION ALERT: Schall Law Firm Encourages Enochian Biosciences, Inc. Investors With $100,000 Losses to Contact Firm


AMD Investors Should Be Excited About These 3 Things

Check Also